- Home
- ANEB vs EQ Comparison
ANEB vs EQ Comparison
Compare ANEB & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANEB
- EQ
- Stock Information
- Founded
- ANEB 2020
- EQ 2017
- Country
- ANEB United States
- EQ United States
- Employees
- ANEB N/A
- EQ N/A
- Industry
- ANEB Biotechnology: Pharmaceutical Preparations
- EQ Biotechnology: Pharmaceutical Preparations
- Sector
- ANEB Health Care
- EQ Health Care
- Exchange
- ANEB Nasdaq
- EQ Nasdaq
- Market Cap
- ANEB 98.6M
- EQ 85.1M
- IPO Year
- ANEB 2021
- EQ 2018
- Fundamental
- Price
- ANEB $2.28
- EQ $1.51
- Analyst Decision
- ANEB Buy
- EQ Hold
- Analyst Count
- ANEB 2
- EQ 2
- Target Price
- ANEB $8.00
- EQ $1.00
- AVG Volume (30 Days)
- ANEB 124.0K
- EQ 834.6K
- Earning Date
- ANEB 11-12-2025
- EQ 11-12-2025
- Dividend Yield
- ANEB N/A
- EQ N/A
- EPS Growth
- ANEB N/A
- EQ N/A
- EPS
- ANEB N/A
- EQ N/A
- Revenue
- ANEB N/A
- EQ $16,553,000.00
- Revenue This Year
- ANEB N/A
- EQ N/A
- Revenue Next Year
- ANEB N/A
- EQ N/A
- P/E Ratio
- ANEB N/A
- EQ N/A
- Revenue Growth
- ANEB N/A
- EQ N/A
- 52 Week Low
- ANEB $0.80
- EQ $0.27
- 52 Week High
- ANEB $3.42
- EQ $2.35
- Technical
- Relative Strength Index (RSI)
- ANEB 42.33
- EQ 51.72
- Support Level
- ANEB $2.34
- EQ $1.31
- Resistance Level
- ANEB $2.47
- EQ $1.54
- Average True Range (ATR)
- ANEB 0.12
- EQ 0.12
- MACD
- ANEB -0.02
- EQ -0.02
- Stochastic Oscillator
- ANEB 13.49
- EQ 62.41
About ANEB Anebulo Pharmaceuticals Inc.
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing treatments for cannabinoid overdose and substance addiction. Its principal product candidate, ANEB-001 (Selonabant), is designed to rapidly counteract the negative effects of cannabis toxicity, including unintentional cannabis poisoning and acute cannabinoid intoxication. The company is focusing on addressing the unmet medical needs in the treatment of cannabinoid toxicity through various therapies.
About EQ Equillium Inc.
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.